Freke Mertens

Ms. Freke Mertens

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MBMurat BOZDAG
Murat BOZDAG
FMFreke Mertens
Freke Mertens
AMAn Matheeussen
An Matheeussen
NPNatascha Van Pelt
Natascha Van Pelt
KFKenn Foubert
Kenn Foubert
PVPieter Van Der Veken
Pieter Van Der Veken
Herein, we report a series of 1,3-diarylpyrazoles that are analogues of compound 26/HIT 8. We previously identified this molecule as a ‘hit’ during a high-throughput screening campaign for autophagy inducers. A variety of synthetic strategies were utilized to modify the 1,3-diarylpyrazole core at its 1-, 3-, and 4-position. Compounds were assessed in vitro to identify their cytotoxicity properties. Of note, several compounds in the series displayed relevant cytotoxicity, which warrants scrutiny while interpreting biological activities that have been reported for structurally related molecules. In addition, antiparasitic activities were recorded against a range of human-infective protozoa, including Trypanosoma cruzi, T. brucei rhodesiense, and Leishmania infantum. The most interesting compounds displayed low micromolar whole-cell potencies against individual or several parasitic species, while lacking cytotoxicity against human cells.

23 December 2025 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
RRRani Robeyns
Rani Robeyns
FMFreke Mertens
Freke Mertens
ASAngela Sisto
Angela Sisto
MLMaria van de Lavoir
Maria van de Lavoir
MDMaria del Mar Delgado-Povedano
Maria del Mar Delgado-Povedano
Alexander L. N. Van NuijsAlexander L. N. Van Nuijs
Alexander L. N. Van Nuijs

7 August 2025 in Autophagy Reports
Verified
Journal Article
Open access
MLMélissa Lallier
Mélissa Lallier
RRRani Robeyns
Rani Robeyns
FMFreke Mertens
Freke Mertens
ASAngela Sisto
Angela Sisto
GMGuido De Meyer
Guido De Meyer
PVPieter Van Der Veken
Pieter Van Der Veken
Targeting autophagy is believed to hold great promise for the treatment of various diseases, including cancer. However, since the therapeutic efficacy of currently available autophagy-modulating drugs is limited by off-target effects and the requirement of high dosage, there is an urgent need to develop novel autophagy-targeting compounds. In this study, we report molecules of the biarylacetamide class as novel autophagy inhibitors. These molecules were identified via phenotypic high-throughput screening, and a series of analogues was subsequently synthesized. Among these, 5d and 5j were retained as potent autophagy blockers in HeLa and LNCaP cells. Both compounds inhibited autophagy at a late-stage in the pathway, as evidenced by the strong accumulation of RFP-GFP-LC3 puncta as well as LC3-II, GABARAP-II and SQSTM1 protein levels, resembling the effects obtained with the well-known late-stage autophagy inhibitor Bafilomycin A1. Quantitative proteome profiling combined with metabolomic and lipidomic studies revealed that 5j significantly altered lipid metabolism. These alterations included activation of the cholesterol biosynthesis pathway and changes in the distribution of key lipid classes, such as phospholipids, ceramides and triglycerides. Further mechanistic studies indicated that 5d and 5j triggered an ER stress response and may impair lysosomal function, as suggested by the accumulation of pro-cathepsin D. Collectively, these findings demonstrate that 5j is a novel and potent late-stage autophagy inhibitor with a distinct mechanism of action compared to currently available inhibitors.

9 May 2026 in European Journal of Pharmacology
Verified
Journal Article
Closed access
FMFreke Mertens
Freke Mertens
FTFarnaz Sedigheh Takhsha
Farnaz Sedigheh Takhsha
MLMélissa Lallier
Mélissa Lallier
Nikolai EngedalNikolai Engedal
Nikolai Engedal
VGVera Goossens
Vera Goossens
WMWim Martinet
Wim Martinet